[go: up one dir, main page]

AR027464A1 - Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh) - Google Patents

Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh)

Info

Publication number
AR027464A1
AR027464A1 ARP010100764A ARP010100764A AR027464A1 AR 027464 A1 AR027464 A1 AR 027464A1 AR P010100764 A ARP010100764 A AR P010100764A AR P010100764 A ARP010100764 A AR P010100764A AR 027464 A1 AR027464 A1 AR 027464A1
Authority
AR
Argentina
Prior art keywords
represents hydrogen
lower alkyl
diseases
agent
halo
Prior art date
Application number
ARP010100764A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004392A external-priority patent/GB0004392D0/en
Priority claimed from GB0015877A external-priority patent/GB0015877D0/en
Priority claimed from GB0020322A external-priority patent/GB0020322D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR027464A1 publication Critical patent/AR027464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen compuestos de la formula general (1) en donde: R1 representa heterociclilo; R2 representa hidrogeno, alquilo infeior sin substituir, alcoxiloinferior, halo, hidroxilo o ciano; R3 representa hidrogeno, alquilo inferior sin substituir, alc oxilo inferior, halo o ciano; R4 representa hidrogeno, alquiloinferior, cicloalquilo inferior, arilo o heterociclilo; R5 representa hidrogeno, alquilo inferior sin substituir, alcoxilo inferior, halo o ciano; R6representa hidrogeno, alquilo inferior sin substituir, alcoxilo inferior, halo o ciano; R7 representa hidrogeno, o alquilo inferior sin substituir; R8representa hidrogeno, o alquilo inferior sin substituir; o R4 y R8 juntamente con el átomo de nitrogeno al cual están unidos, representan h eterociclilo; y lassales farmacéuticamente aceptables de los mismo. Los derivados de la oxamida descritos son inhibidores de la enzima inosina monofosfato deshidrogenasa (IMPDH).Pueden emplearse como medicamentos, especialmente para el tratamiento de condiciones o enfermedades inmunoinducidas, enfermedades víricas, enfermedadesbacterianas, enfermedades parasitarias, inflamacion, enfermedades inflamatorias, enfermedades vasculares hiperproliferativas, tumores y cáncer. Pudenemplearse solos o en c ombinacion con otros agentes terapéuticamente activos, por ejemplo, un inmunosupresor, un agente quimioterapéutico, un agenteantivírico, un antibiotico, un agente antipararsitario, un agente antiinflamatorio, un agente antifungico y/o un agente de an tihiperproliferacion vascular.
ARP010100764A 2000-02-24 2001-02-21 Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh) AR027464A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0004392A GB0004392D0 (en) 2000-02-24 2000-02-24 Oxamide derivatives
GB0015877A GB0015877D0 (en) 2000-06-28 2000-06-28 Oxamide derivatives
GB0020322A GB0020322D0 (en) 2000-08-17 2000-08-17 Oxamide derivatives

Publications (1)

Publication Number Publication Date
AR027464A1 true AR027464A1 (es) 2003-03-26

Family

ID=27255557

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100764A AR027464A1 (es) 2000-02-24 2001-02-21 Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh)

Country Status (8)

Country Link
US (1) US6867299B2 (es)
EP (1) EP1127883A3 (es)
JP (1) JP2001261663A (es)
KR (1) KR20010085490A (es)
CN (1) CN1310179A (es)
AR (1) AR027464A1 (es)
BR (1) BR0100790A (es)
CA (1) CA2337588A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1707700A (en) 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
EP1577302A4 (en) * 2002-12-24 2010-09-01 Daiichi Seiyaku Co NOVEL ETHYLENEDIAMINE DERIVATIVES
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
BRPI0407968A (pt) * 2003-03-24 2006-03-07 Merck Patent Gmbh derivados de oxamida úteis como inibidores de raf-quinase
ES2337576T3 (es) * 2003-04-23 2010-04-27 Japan Tobacco Inc. Antagonista decasr.
GB0326393D0 (en) * 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
EA011097B1 (ru) 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AU2005279209B2 (en) 2004-08-30 2011-03-24 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-BETA hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
ES2338441T3 (es) 2004-08-30 2010-05-07 Janssen Pharmaceutica Nv Derivados de n-2-adamantil-2-fenoxi-acetamida como inhibidores de 11-betahidroxiesteroide-deshidrogenasa.
WO2007143557A2 (en) * 2006-06-02 2007-12-13 Brandeis University Compounds and methods for treating mammalian gastrointestinal parasitic infections
KR20100061692A (ko) * 2007-09-21 2010-06-08 사노피-아벤티스 （카복실알킬렌-페닐）-페닐-옥살아미드, 이의 제조 방법 및 의약으로서의 이의 용도
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
WO2010053583A2 (en) * 2008-11-10 2010-05-14 Dana Farber Cancer Institute Small molecule cd4 mimetics and uses thereof
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
WO2012020484A1 (ja) * 2010-08-11 2012-02-16 アグロカネショウ株式会社 ３-アミノオキサリルアミノベンズアニリド誘導体及びこれを有効成分とする殺虫、殺ダニ剤
WO2012020483A1 (ja) * 2010-08-11 2012-02-16 アグロカネショウ株式会社 ３-アミノオキサリルアミノベンズアミド誘導体及びこれを有効成分とする殺虫、殺ダニ剤
EP2753176A4 (en) * 2011-09-06 2015-10-21 New York Blood Ct Inc HIV INHIBITORS
US8916702B2 (en) * 2012-02-06 2014-12-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN107569483B (zh) 2012-06-08 2021-09-17 高等教育联邦系统-匹兹堡大学 选自苄星青霉素化合物等的化合物在制备用于治疗炎症疾病的药物中的用途
HUE053325T2 (hu) * 2012-10-31 2021-06-28 Univ Michigan Regents Plazminogén aktivátor-1 gátlók és ezek alkalmazási eljárásai
WO2015089087A1 (en) 2013-12-09 2015-06-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for treating respiratory injury or disease
WO2016025681A1 (en) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibitors of hiv-1 entry and methods of use thereof
CA2960275A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
WO2016044808A1 (en) 2014-09-19 2016-03-24 New York Blood Center, Inc. Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv
JP6906444B2 (ja) 2014-12-10 2021-07-21 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 疾患および状態を処置するための組成物および方法
PL3657946T3 (pl) 2017-07-27 2025-03-31 The Regents Of The University Of Michigan Inhibitor aktywatora plazminogenu-1 (pai-1) i sposób jego zastosowania
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
CN109503528B (zh) * 2018-05-15 2022-06-14 天津国际生物医药联合研究院 一种化合物及其在抗沙粒病毒感染中的应用
WO2020198431A1 (en) * 2019-03-26 2020-10-01 University Of Cincinnati Method of making prodrug for sustained and controlled release
CN109824583B (zh) * 2019-03-27 2022-04-08 山东大学 一种苯基草酰胺类hiv-1抑制剂及其制备方法和应用
US20210315880A1 (en) 2020-03-20 2021-10-14 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN112851627B (zh) * 2021-03-08 2022-03-18 苏州大学 小分子化合物及其用途和组合物
CN119424419B (zh) * 2024-12-26 2025-08-08 桂林医学院附属医院 一种草酰胺类化合物在制备抗肝癌药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463774A1 (fr) 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
GB8310435D0 (en) 1983-04-18 1983-05-25 Fujisawa Pharmaceutical Co Triazine derivatives
US5362481A (en) 1993-03-05 1994-11-08 3V Inc. Benzofuran derivatives and the use thereof as stabilizers against UV radiations
DE69624728T2 (de) 1995-12-29 2003-07-10 Boehringer Ingelheim (Canada) Ltd., Laval Phenyl thiazol derivate mit antiherpesvirus eigenschaften
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
EP0902782A1 (en) 1996-04-23 1999-03-24 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
US5932600A (en) 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
EP1027051B1 (en) 1997-04-30 2005-01-05 Eli Lilly And Company Antithrombotic agents
WO1999046236A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
JP2004500308A (ja) 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
AU3665199A (en) 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
AU1707700A (en) * 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme

Also Published As

Publication number Publication date
KR20010085490A (ko) 2001-09-07
EP1127883A3 (en) 2002-08-07
EP1127883A2 (en) 2001-08-29
CN1310179A (zh) 2001-08-29
US6867299B2 (en) 2005-03-15
JP2001261663A (ja) 2001-09-26
BR0100790A (pt) 2001-09-25
US20020052513A1 (en) 2002-05-02
CA2337588A1 (en) 2001-08-24

Similar Documents

Publication Publication Date Title
AR027464A1 (es) Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh)
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
EE200200091A (et) N-heterotsüklilised derivaadid kui NOSi inhibiitorid
ATE472535T1 (de) Pyrimidinmatrixmetalloproteinaseinhibitoren
MXPA05000388A (es) Derivados de flavona como inhibidores de cinasas dependientes de la ciclina.
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
ATE437872T1 (de) Proteinkinaseinhibitoren
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
PT1268471E (pt) Derivados n-heterociclicos como inibidores de nos
TW430660B (en) Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
BR9710737A (pt) Pentafluorobenzenosulfonamidas e análogos.
RU2007110629A (ru) Ингибиторы днк-пк
ATE450499T1 (de) Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
WO2000064874A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
CA2663965A1 (en) Pyrazolopyrimidine derivative and use thereof as an anticancer agent
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
CA2487252A1 (en) Esters in position 20 of camptothecins
KR910014119A (ko) 항-고혈압 활성을 갖는 티아졸리딘 유도체 및 그의 치료용도
ATE457306T1 (de) 4-aryl substituierte chinole und analoga als therapeutische wirkstoffe
PT1095040E (pt) Novos benzoxazoles com actividade inibidora da pde
ATE263183T1 (de) A-500359-derivate

Legal Events

Date Code Title Description
FB Suspension of granting procedure